Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease

R.C. Melchers; R. Willemze; J.S.P. Vermaat; P.M. Jansen; L.A. Daniels; H. Putter; M.W. Bekkenk; E.R.M. de Haas; B. Horvath; M.M. van Rossum; C.J.G. Sanders; J.C.J.M. Veraart; M.H. Vermeer; K.D. Quint

doi:10.1182/blood.2019002799

Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease

R.C. Melchers, R. Willemze, J.S.P. Vermaat, P.M. Jansen, L.A. Daniels, H. Putter, M.W. Bekkenk, E.R.M. de Haas, B. Horvath, M.M. van Rossum, C.J.G. Sanders, J.C.J.M. Veraart, M.H. Vermeer, K.D. Quint

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	769-773
Number of pages	6
Journal	Blood
Volume	135
Issue number	10
DOIs	https://doi.org/10.1182/blood.2019002799
Publication status	Published - 5 Mar 2020

Keywords

brentuximab vedotin
classification
diagnosis
eortc
guidelines
iscl
large-cell lymphoma
papulosis
DIAGNOSIS
PAPULOSIS
EORTC
GUIDELINES
BRENTUXIMAB VEDOTIN
CLASSIFICATION
LARGE-CELL LYMPHOMA
ISCL

Access to Document

10.1182/blood.2019002799

Cite this

Melchers, R. C., Willemze, R., Vermaat, J. S. P., Jansen, P. M., Daniels, L. A., Putter, H., Bekkenk, M. W., de Haas, E. R. M., Horvath, B., van Rossum, M. M., Sanders, C. J. G., Veraart, J. C. J. M., Vermeer, M. H., & Quint, K. D. (2020). Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease. Blood, 135(10), 769-773. https://doi.org/10.1182/blood.2019002799

Melchers, R.C. ; Willemze, R. ; Vermaat, J.S.P. ; Jansen, P.M. ; Daniels, L.A. ; Putter, H. ; Bekkenk, M.W. ; de Haas, E.R.M. ; Horvath, B. ; van Rossum, M.M. ; Sanders, C.J.G. ; Veraart, J.C.J.M. ; Vermeer, M.H. ; Quint, K.D. / Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease. In: Blood. 2020 ; Vol. 135, No. 10. pp. 769-773.

@article{85212572109f4d219b0f6d071717bb03,

title = "Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease",

keywords = "brentuximab vedotin, classification, diagnosis, eortc, guidelines, iscl, large-cell lymphoma, papulosis, DIAGNOSIS, PAPULOSIS, EORTC, GUIDELINES, BRENTUXIMAB VEDOTIN, CLASSIFICATION, LARGE-CELL LYMPHOMA, ISCL",

author = "R.C. Melchers and R. Willemze and J.S.P. Vermaat and P.M. Jansen and L.A. Daniels and H. Putter and M.W. Bekkenk and {de Haas}, E.R.M. and B. Horvath and {van Rossum}, M.M. and C.J.G. Sanders and J.C.J.M. Veraart and M.H. Vermeer and K.D. Quint",

year = "2020",

month = mar,

day = "5",

doi = "10.1182/blood.2019002799",

language = "English",

volume = "135",

pages = "769--773",

journal = "Blood",

issn = "0006-4971",

publisher = "The American Society of Hematology",

number = "10",

}

Melchers, RC, Willemze, R, Vermaat, JSP, Jansen, PM, Daniels, LA, Putter, H, Bekkenk, MW, de Haas, ERM, Horvath, B, van Rossum, MM, Sanders, CJG, Veraart, JCJM, Vermeer, MH & Quint, KD 2020, 'Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease', Blood, vol. 135, no. 10, pp. 769-773. https://doi.org/10.1182/blood.2019002799

Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease. / Melchers, R.C.; Willemze, R.; Vermaat, J.S.P.; Jansen, P.M.; Daniels, L.A.; Putter, H.; Bekkenk, M.W.; de Haas, E.R.M.; Horvath, B.; van Rossum, M.M.; Sanders, C.J.G.; Veraart, J.C.J.M.; Vermeer, M.H.; Quint, K.D.

In: Blood, Vol. 135, No. 10, 05.03.2020, p. 769-773.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease

AU - Melchers, R.C.

AU - Willemze, R.

AU - Vermaat, J.S.P.

AU - Jansen, P.M.

AU - Daniels, L.A.

AU - Putter, H.

AU - Bekkenk, M.W.

AU - de Haas, E.R.M.

AU - Horvath, B.

AU - van Rossum, M.M.

AU - Sanders, C.J.G.

AU - Veraart, J.C.J.M.

AU - Vermeer, M.H.

AU - Quint, K.D.

PY - 2020/3/5

Y1 - 2020/3/5

KW - brentuximab vedotin

KW - classification

KW - diagnosis

KW - eortc

KW - guidelines

KW - iscl

KW - large-cell lymphoma

KW - papulosis

KW - DIAGNOSIS

KW - PAPULOSIS

KW - EORTC

KW - GUIDELINES

KW - BRENTUXIMAB VEDOTIN

KW - CLASSIFICATION

KW - LARGE-CELL LYMPHOMA

KW - ISCL

U2 - 10.1182/blood.2019002799

DO - 10.1182/blood.2019002799

M3 - Comment/Letter to the editor

C2 - 31977038

VL - 135

SP - 769

EP - 773

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -